Curated news and analysis on clinical trials, drug approvals, and medical research.
Xenon Pharmaceuticals will announce topline data from its Phase 3 X-TOLE2 study of azetukalner in patients with focal onset seizures on March 9, 2026, during a conference call at 8:00 a.m. ET.
Compass Pathways announced positive Phase 3 data for COMP360 psilocybin therapy in treatment-resistant depression, showing statistically significant improvements in depression scores and durability through 26 weeks, with plans to file for FDA approval in Q4 2026.
COMPASS Pathways announced positive Phase 3 results for COMP360 psilocybin in treatment-resistant depression, showing statistically significant improvements across two pivotal trials with durability signals through 26 weeks and a generally well-tolerated safety profile.
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Nigeria's National Biosafety Management Agency reassures citizens that no GMO food is approved without thorough safety assessment, while critics question the absence of long-term independent risk studies and transparency in the regulatory process.
New research reveals GPs spend only 56% of their time with patients, while 31% goes to non-contact clinical work that remains largely unfunded, contributing to workforce burnout and retention issues.
More than 16,000 dermatology trials were completed, ongoing, or planned by the end of 2025, with the Asia-Pacific region experiencing a nearly five-fold increase over the past decade. The field now accounts for around 8,000 trials in Asia-Pacific alone, matching North America and Europe combined.
Pfizer is applying lessons from its Viagra launch to introduce its first obesity treatment, a monthly injection acquired from Metsera. The company aims to leverage past experience with sensitive health topics as it enters the competitive obesity market.
Orforglipron, an oral GLP-1 receptor agonist, demonstrated greater reductions in HbA1c and body weight compared to oral semaglutide in adults with type 2 diabetes, with more patients achieving strict glycemic targets at one year.
Novartis announced positive European regulatory opinion for remibrutinib in chronic spontaneous urticaria and reported the drug met its primary endpoint in a Phase 3 trial for chronic inducible urticaria.
Maryland-based CDMO Xcellon Biologics introduces the Xcellerate Program to provide early-stage biotech companies with reduced-cost development support for complex biologics and antibody-drug conjugates, addressing the funding gap between seed stage and institutional investment.
New research shows genomic profiling can detect aggressive prostate cancer not identified at biopsy, while a separate study reveals PTGES3 as a potential therapeutic target for treatment-resistant disease.
C4 Therapeutics has initiated its Phase 2 MOMENTUM trial of cemsidomide in relapsed/refractory multiple myeloma, targeting enrollment completion in Q1 2027 and a registrational dataset by 2028. The company plans a combination study with elranatamab in Q2 2026.
Four months after the Gaza ceasefire declaration, over 570 Palestinians have been killed amid ongoing violence. Phase II negotiations show no progress expected until late February, with disputes over governance and security arrangements delaying implementation.
A six-year study in Liberia found that 11% of patients admitted with fever had undiagnosed Lassa fever, with mortality exceeding 20% in some settings and children comprising 43% of confirmed cases.
Scientists at three institutions have developed distinct nanoparticle-based drug delivery systems designed to target cancer tumors more precisely while reducing side effects, with approaches ranging from DNA nanomachines to transformable nanofibers.
Novo Nordisk struggles against Eli Lilly in the weight loss market as CagriSema underperforms Zepbound, though new candidate UBT251 shows promise with 19.7% weight loss in 24 weeks. The company expects sales to decline in 2026 despite oral Wegovy's success.
Danaher approved a $0.40 quarterly dividend and completed a $9.9 billion Masimo acquisition to expand into patient monitoring, while its Life Sciences segment operating profit fell 57% in 2025 to $520 million.
Scientists at UCL have discovered that the protein LRG1 triggers the earliest damage in diabetic retinopathy by constricting retinal blood vessels. Blocking LRG1 in diabetic mice prevented early retinal damage and preserved normal eye function.
Baili Pharmaceutical Group Co., Ltd. is offering 8,634,300 H Shares on the Hong Kong Stock Exchange at HK$347.50 to HK$389.00 per share, with listing expected November 17, 2025. Bristol-Myers Squibb leads cornerstone investors with US$15 million commitment.
